Диссертация (1140225), страница 17
Текст из файла (страница 17)
2006; 4:25-3018. Милованова С.Ю., Игнатова Т.М., Козловская Л.В. Особенности теченияхроническогогепатитаСскриоглобулинемией,Клиническаягепатология. 2006; 2(1): 15-18.19. Милованова С.Ю., Тэгай С.В., Русских А.В., Козловская Л.В.Особенности поражения почек у больных хроническим гепатитом С скриоглобулинемией. Терапевтический архив. 2011; 83(11): 38-44.20. Мухин Н.А. Клинические проблемы амилоидоза почек. Клиническаямедицина. 1983; 10: 12-17.21. Мухин Н.А., Козловская Л.В., Малышко Е.Ю.
Криоглобулинемическийнефрит, ассоциированный с хронической инфекцией вируса гепатита С.Терапевтический архив. 2000; (6): 1-5.22. Мухин Н.А., Козловская Л.В., Милованова Л.Ю. и др. HCVассоциированныйкриоглобулинемическийваскулитстяжелымпоражением почек и развитием В-клеточной лимфомы.
Современныевозможности изменения прогноза с помощью моноклональных антител110к CD20 и противовирусной терапии. Клиническая нефрология. 2011; (2):61-9.23. Рамеев В. В., Козловская Л. В., Саркисова И. А. Амилоидоз: вопросыдиагностики и лечения. Клиницист. 2006; 4: 35-41.24. Рамеев В.В., Козловская Л.В, Малинина Е.А., Серова А.Г., Когарко И.Н.,Когарко Б.С., Любимова Н.В.
Современные методы диагностики имониторирования течения системного амилоидоза. Терапевтическийархив. 2011; 83 (8): 48-54.25. Рамеев В., Козловская Л., Гудкова К., Когарко И., Когарко Б.Первичный AL-амилоидоз: новое в представлениях о патогенезе,диагностике и лечении. Врач. 2013; 1: 58-61.26. Тэгай С.В., Коротчаева Ю.В., Милованова С.Ю., Козловская Л.В.Клиническое значение смешанной криоглобулинемии у больных споражением почек.
Клиническая лабораторная диагностика. 2002; 9: 33.27. Тэгай С.В., Лопаткина Т.Н., Косминкова Е.Н., Козловская Л.В.Поражение почек, ассоциированное с вирусами гепатитов В и С.Consilium Medicum. 2002; 4 (7): 337-41.28. М. С. Храброва, В. А. Добронравов, А. В. Смирнов. Поражения почек,ассоциированные с моноклональными гаммапатиями: одноцентровоеисследование.Нефрология.2018;22(6):38-46.https://doi.org/10.24884/1561-6274-2018-22-6-38-46.29. Шевченко О.П., Долгов В.В., Олефиренко Г.А. Электрофорез вклинической лаборатории 1т.
М. Реафарм, 2006.30. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA,Fonseca R. Immunoglobulin light chain variable (V) region genes influenceclinical presentation and outcome in light chain-associated amyloidosis (AL).Blood. 2003; 101(10):3801-3018; doi: 10.1182/blood-2002-09-2707.31.
Basnayake K, Stringer S, Hutchison C, Cockwell P. The biology ofimmunoglobulin free light chains and kidney injury. Kidney International.2011; 79:1289-1301. doi: 10.1038/ki.2011.11132. Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol. 2007; 153:87-104. doi: 10.1159/00009676233. Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chainamyloidosis — the archetype of structural and pathogenic variability.
J StructBiol. 2000; 130(2-3):280-289. doi: 10.1006/jsbi.2000.4248.34. Bida JP, Kyle RA, Therneau TM, Melton LJ 3rd, Plevak MF, Larson DR,Dispenzieri A, Katzmann JA, Rajkumar SV. Disease associations withmonoclonal gammopathy of undetermined significance: a population-basedstudy of 17,398 patients. Mayo Clin Proc. 2009; 84(8):685–93. doi:10.1016/S0025-6196(11)60518-1.35. Brebner JA, Stockley RA. Polyclonal free light chains: a biomarker ofinflammatory disease or treatment target? F1000 Med Rep. 2013;5:4. doi:10.3410/M5-4.36. Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM,Lacombe C, Quellard N, Touchard G.
Glomerulonephritis with isolated C3deposits and monoclonal gammopathy: a fortuitous association? Clin. J. Am.Soc. Nephrol. 2011; 6 (9): 2165—74. doi: 10.2215/CJN.06180710.37. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP,Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC,Dispenzieri A, Kyle RA, Nasr SH; International Kidney and MonoclonalGammopathy Research Group. Diagnosis of monoclonal gammopathy ofrenalsignificance.KidneyInt.2015;87(4):698-711.doi:10.1038/ki.2014.408.38.
Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic andclinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775-88.39. Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S,Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V,Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, BridouxF. Treatment of B-cell disorder improves renal outcome of patients with112monoclonal gammopathy-associated C3 glomerulopathy. Blood.
2017 Mar16;129(11):1437-1447. doi: 10.1182/blood-2016-08-737163.40. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM,Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, DorosG, Blade J, Skinner M. Outcome of AL amyloidosis after high-dosemelphalan and autologous stem cell transplantation: long-term results in aseries of 421 patients. Blood. 201; 118(16):4346-52. doi: 10.1182/blood2011-01-330738.41.
Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences inthe prevalence of monoclonal gammopathy in a community-based sample ofthe elderly. Am J Med. 1998; 104(5):439-44.42. Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C,Aucouturier P, Godin M, Ronco P. Recurrent membranous nephropathy in anallograft caused by IgG3κ targeting the PLA2 receptor. J Am Soc Nephrol.2012; 23(12):1949-54. doi: 10.1681/ASN.2012060577.43. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, ChananKhan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M,Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S,Giralt S, Munshi NC, Jagannath S; International Myeloma WorkshopConsensus Panel 3. Consensus recommendations for standard investigativeworkup: report of the International Myeloma Workshop Consensus Panel 3.Blood.2011; 117(18): 4701–5.
doi: 10.1182/blood-2010-10-299529.44. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, PalumboA, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H,Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P,Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV,Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV,Durie BG; International Myeloma Working Group. International MyelomaWorking Group guidelines for serum-free light chain analysis in multiple113myeloma and related disorders.
Leukemia 23: 215-224, 2009. doi:10.1038/leu.2008.307.45. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, ColbyCL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF,Rajkumar SV. Prevalence and risk of progression of light-chain monoclonalgammopathy of undetermined significance: A retrospective population-basedcohort study. Lancet. 2010; 375: 1721-8. doi: 10.1016/S0140-6736(10)604825.46. Doyle LM, Gundrum JD, Farnen JP, Wright LJ, Kranig JAI, Go RS.Determining why and which clinicians order serum protein electrophoresis(SPEP), subsequent diagnoses based on indications, and clinical significanceof routine follow-up: a study of patients with monoclonal gammopathy ofundetermined significance (MGUS). Blood.
2009; 114(22): 4883.47. Gertz M. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis,risk-stratification, and management. Am. J. Hematol. 2011; 86: 181-6. doi:10.1002/ajh.21934.48. Go RS, Swanson KM, Sangaralingham LR, Habermann EB, Shah ND.Clinical prevalence (diagnosed cases) of monoclonal gammopathy ofundetermined significance in the US: estimating the burden on health care.Leukemia. 2016; 30(6):1443-6. doi: 10.1038/leu.2015.336.49. Go RS, Heien HC, Sangaralingham LR, Habermann EB, Shah ND.
Risk ofprogression of monoclonal gammopathy of undetermined significance intolymphoplasmacytic malignancies: determining demographic differences in theUSA.Haematologica. 2018; 103(3): e123-e125. doi: 10.3324/haematol.2017.179978.50. Go RS, Rajkumar SV. How I manage monoclonal gammopathy ofundetermined significance. Blood. 2018; 131(2):163-173. doi: 10.1182/blood2017-09-807560.51. Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: apoorly recognized pattern of renal disease in patients with plasma cell114dyscrasia.
Arch Pathol Lab Med: 2006; 130(2): 165-9. doi: 10.1043/15432165(2006)130[165:LATINA]2.0.CO;2.52. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term followup and response to chemotherapy in patients with light-chain depositiondisease. Am J Kidney Dis. 1992; 20(1):34-41.53. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternativetest to urine Bence Jones proteins when screening for monoclonalgammopathies.ClinChem52:1743-1748,2006.doi:10.1373/clinchem.2006.069104.54. Hogan JJ, Weiss BM. Bridging the divide: an onco-nephrologic approach tothe monoclonal gammopathies of renal significance. Clin J Am Soc Nephrol.2016; 11(9):1681–1691. doi:10.2215/CJN.03160316.55.
Al-Hussain T, Hussein MH, Al Mana H, Akhtar M. Renal involvement inmonoclonal gammopathy. Adv Anat Pathol. 2015; 22(2):121-34. doi:10.1097/PAP.0000000000000056.56. Hutchison C., Basnayake K., Cockwell P. Serum free light chain assessmentin monoclonal gammopathy and kidney disease. Nature Rev.
Nephrol. 2009;5: 621-7. doi:10.1038/nrneph.2009.151.57. Jenner E. Serum free light chains in clinical laboratory diagnostics. Clin ChimActa. 2014; 427:15-20. doi: 10.1016/j.cca.2013.08.018.58. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. Nephritogeniclambda light chain dimer: a unique human miniautoantibody against factor H.J Immunol. 1999; 163:4590-6.59. Kapoulas S, Raptis V, Papaioannou M New aspects on the pathogenesis ofrenal disorders related to monoclonal gammopathies. Nephrol Ther.
2015;11(3): 135-143. doi: 10.1016/j.nephro.2014.12.005.60. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR,Kyle RA. Serum reference intervals and diagnostic ranges for free and freeimmunoglobulin light chains: Relative sensitivity for detection of monoclonallight chains. Clin. Chem. 2002; 48 (9): 1437-44.
PMID: 12194920.11561. Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR,Abraham RS, Lust JA, Melton LJ 3rd, Rajkumar SV. Elimination of the needfor urine studies in the screening algorithm for monoclonal gammopathies byusing serum immunofixation and free light chain assays.
Mayo Clin Proc.2006; 81(12):1575-8. doi: 10.4065/81.12.1575.62. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA,Rajkumar SV, Dispenzieri A. Screening panels for detection of monoclonalgammopathies.Clin.Chem.2009;55(8):1517-22.doi:10.1373/clinchem.2009.126664.63. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain depositiondisease light chains induce divergent phenotypic transformations of humanmesangial cells.
Lab Invest. 2004; 84(10): 1322-38.64. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodelingin light chain-related glomerular damage. Kidney Int. 2005; 68(4):1590-603.doi: 10.1111/j.1523-1755.2005.00571.x.65. Knight GB, Gao L, Gragnani L, Elfahal MM, De Rosa FG, Gordon FD,Agnello V. Detection of WA B cells in hepatitis C virus infection: a potentialprognostic marker for cryo-globulinemic vasculitis and B cell malignancies.Arthr. and Rheum.
2010; 62: 2152-9. doi: 10.1002/art.27490.66. Kyle RA. Monoclonal gammopathy of undetermined significance: naturalhistory in 241 cases. Am J Med. 1978;64:814-826.67. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ3rd. Long-term follow-up of 241 patients with monoclonal gammopathy ofundetermined significance: the original Mayo Clinic series 25 years later.Mayo Clin Proc. 2004; 79(7):859-66. doi: 10.1016/S0025-6196(11)62151-4.68.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
